Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Orthocell.
RELATED STOCKHEAD STORIES
News
Rise and Shine: Everything you need to know before the ASX opens
Health & Biotech
ASX Health Stocks: Forget surgery, Orthocell says tennis elbow can be fixed with its tendon cell therapy
Health & Biotech
ASX Health Stocks: Neuren’s breakthrough Rett Syndrome drug DAYBUE is now officially available in the US
Health & Biotech
ASX Health Stocks: Woolworths’ subsidiary partners with Telehealth stock Global Health, share price up 5pc
Health & Biotech
ASX Biotech Stocks: Surgeons can now be reimbursed for using Orthocell’s nerve repair device
Health & Biotech
ASX Health Stocks: New dawn for Alzheimer’s after Biogen’s landmark results; Cogstate soars by proxy
News
Market Highlights: BoE triggers huge market rally, and 5 ASX small caps to watch on Thursday
Health & Biotech
ASX Health Stocks: Race to develop RNA-based therapies is well and truly on, as these two biotechs add new programs
Investor Guides
Investor Guide: Health & Biotech FY2023
Health & Biotech
ASX Health Stocks: Orthocell up 35pc after shaking on exclusive global patent deal
News
Closing Bell: Vulcan and Leo prove there’s two sides to the lithium coin as the ASX closes the week out ahead
Health & Biotech
Cast your eyes over these 15 weird and wonderful biotech stocks we found on the ASX
Health & Biotech
Check Up: Biotechs are getting crushed, but expert says we shouldn’t dismiss them
Health & Biotech
ASX Health Stocks: Orthocell reports positive results from nerves reconstruction trial
Health & Biotech
ASX Health Stocks: TGA gives Orthocell green light for its nerve repair device Remplir
Health & Biotech
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
Health & Biotech